Global Respiratory Drugs Market 2016-2020

  • ID: 3721870
  • Report
  • Region: Global
  • 120 pages
  • TechNavio
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

1 of 5

FEATURED COMPANIES

  • Abbott
  • Aurobindo
  • Cipla
  • GNI Group Ltd
  • Perrigo
  • Skyepharma
  • MORE
About Respiratory Ailments

Asthma, COPD, allergic rhinitis, pulmonary hypertension, cystic fibrosis, and IPF are some of the major respiratory diseases. Among these, asthma and COPD are the most prevalent worldwide. Environmental pollution, changing lifestyles, and hereditary factors are some of the common causes of respiratory diseases. Intranasal corticosteroids, antihistamines, immunosuppressants, bronchodilators, and leukotriene antagonists are the respiratory medicines that are commonly used for the treatment of mild-to-moderate respiratory diseases. However, the choice of drug depends on the type and severity of the disease.

The analysts forecast the global respiratory drugs market to grow at a CAGR of 6.48% during the period 2016-2020.

Covered in this report
The report covers the present scenario and the growth prospects of the global respiratory drugs market for 2016-2020. To calculate the market size, the report considers the revenue generated from the sales of prescription and over-the-counter (OTC) drugs used to treat respiratory diseases.

The market is divided into the following segments based on geography:
- Americas
- APAC
- EMEA

The report, Global Respiratory Drugs Market 2016-2020, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the market landscape and its growth prospects over the coming years. The report also includes a discussion of the key vendors operating in this market.

Key vendors
- AstraZeneca
- Boehringer Ingelheim
- F.Hoffman La-Roche
- GlaxoSmithKline
- Merck
- Novartis

Other prominent vendors
- Abbott
- Actavis
- Afferent Pharmaceuticals
- Alere
- Almirall
- Amgen
- AptarGroup
- Astellas
- Aurobindo
- Axis Shield
- Baxter
- Bayer
- Biogen
- Biotest
- Bristol-Myers Squibb
- Chiesi Farmaceutici
- Cipla
- Cytos
- Dainippon Sumitomo
- Dr. Reddy's Laboratories
- FibroGen
- Gilead Sciences
- Glenmark
- GNI Group Ltd
- Horizon Pharma
- ImmuneWorks
- MediciNova
- MedImmune
- Mylan
- Ono Pharmaceutical
- Orchid Chemicals and Pharmaceuticals
- Perrigo
- Pfizer
- Promedior
- Prometheus
- ProMetic Life Sciences
- Ranbaxy
- Rottapharm Madaus
- Sanofi
- Shionogi
- Siemens Healthcare Diagnostics
- Skyepharma
- Sosei
Sunovion
- Takeda Pharmaceutical
- Teva
- Theravance
- United Therapeutics
- Vectura
- Vertex
- Zai Lab

Market drivers
- Rise in prevalence of respiratory diseases
- For a full, detailed list, view the full report

Market challenges
- Unknown etiology of asthma and idiopathic pulmonary fibrosis
- For a full, detailed list, view the full report

Market trends
- Use of biologics
- For a full, detailed list, view the full report

Key questions answered in this report
- What will the market size be in 2020 and what will the growth rate be?
- What are the key market trends?
- What is driving this market?
- What are the challenges to market growth?
- Who are the key vendors in this market space?
- What are the market opportunities and threats faced by the key vendors?
- What are the strengths and weaknesses of the key vendors?

You can request one free hour of our analyst’s time when you purchase this market report. Details are provided within the report.
READ MORE
Note: Product cover images may vary from those shown
2 of 5

FEATURED COMPANIES

  • Abbott
  • Aurobindo
  • Cipla
  • GNI Group Ltd
  • Perrigo
  • Skyepharma
  • MORE
PART 01: Executive summary
  • Highlights
PART 02: Scope of the report
  • Market overview
  • Top-vendor offerings
PART 03: Market research methodology
  • Research methodology
  • Economic indicators
PART 04: Introduction
  • Key market highlights
PART 05: Overview: Respiratory diseases
  • Asthma
  • COPD
  • Allergic rhinitis
  • Pulmonary hypertension
  • Cystic fibrosis
  • IPF
  • US FDA-approved respiratory drugs
PART 06: Pipeline analysis
  • Information on some pipeline candidates
PART 07: Market landscape
  • Five forces analysis
PART 08: Market segmentation by class of drugs
  • Bronchodilators
  • Leukotriene antagonists
  • Mast cell stabilizers
  • Immunosuppressants
  • Combination of LABA/ICS
  • Tyrosine kinase inhibitors
  • Antifibrotic agents
  • Antihistamines
  • Endothelin (ET) receptor antagonist
  • Prostacyclin analogs
  • Phosphodiesterase inhibitors
  • Soluble guanylate cyclase (sGC) stimulators
PART 09: Market segmentation by disease
  • Global asthma drugs market
  • Global COPD drugs market
  • Global allergic rhinitis drugs market
  • Global pulmonary hypertension drugs market
  • Global cystic fibrosis drugs market
  • Global IPF drugs market
PART 10: Geographical segmentation
  • Global respiratory drugs market by geography 2015-2020
  • Respiratory drugs market in Americas
  • Respiratory drugs market in EMEA
  • Respiratory drugs market in APAC
PART 11: Market drivers
  • Promising late-stage pipeline molecules
  • Rise in prevalence of respiratory diseases
  • Increase in older adult population
  • High usage of tobacco
  • Increase in environmental pollution
PART 12: Impact of drivers

PART 13: Market challenges
  • Multiple patent expiries
  • Unknown etiology of asthma and IPF
  • Low diagnosis rates
  • Adverse effects of drugs
  • Increased preference for CAM
PART 14: Impact of drivers and challenges

PART 15: Market trends
  • Increasing awareness about respiratory diseases
  • Patient assistance programs
  • Usage of biologics
  • Self-medication using OTC products
  • Strategic alliances
PART 16: Vendor landscape
  • Competitive scenario
  • Market share analysis 2015
  • AstraZeneca
  • Boehringer Ingelheim
  • F. Hoffmann-La Roche
  • GlaxoSmithKline
  • Merck
  • Novartis
  • Other prominent vendors
PART 17: Appendix
  • List of abbreviations
PART 18: About the Author

List of Exhibits
Exhibit 01: Product offerings
Exhibit 02: Objectives of asthma management
Exhibit 03: COPD: Prevalence in six EU countries
Exhibit 04: Management of COPD
Exhibit 05: Prevalence rate of allergic rhinitis in China
Exhibit 06: Summary of pharmacologic treatments for allergic rhinitis
Exhibit 07: Non-pharmacological therapies for allergic rhinitis
Exhibit 08: Prevalence of cystic fibrosis by country 2014
Exhibit 09: Treatment options for IPF
Exhibit 10: Drugs approved by US FDA for respiratory diseases 2000-2015
Exhibit 11: Pipeline portfolio of major drug candidates for respiratory diseases
Exhibit 12: Global respiratory drugs market 2015-2020 ($ billions)
Exhibit 13: Global respiratory drugs market by diseases 2015
Exhibit 14: Five forces analysis
Exhibit 15: Global asthma drugs market 2015-2020 ($ billions)
Exhibit 16: Key drivers and challenges of global asthma drugs market
Exhibit 17: Global asthma drugs market by class of drugs 2015
Exhibit 18: Global COPD drugs market 2015-2020 ($ billions)
Exhibit 19: Key drivers and challenges of global COPD drugs market
Exhibit 20: Global COPD drugs market by class of drugs 2015
Exhibit 21: Global allergic rhinitis drugs market 2015-2020 ($ billions)
Exhibit 22: Key drivers and challenges of global allergic rhinitis drugs market
Exhibit 23: Global allergic rhinitis drugs market by class of drugs 2015
Exhibit 24: Global pulmonary hypertension drugs market 2015-2020 ($ billions)
Exhibit 25: Key drivers and challenges for global pulmonary hypertension drugs market
Exhibit 26: Global pulmonary hypertension drugs market by class of drugs 2015
Exhibit 27: Global cystic fibrosis drugs market 2015-2020 ($ billions)
Exhibit 28: Key drivers and challenges for global cystic fibrosis drugs market
Exhibit 29: Global cystic fibrosis drugs market by type of molecule 2015
Exhibit 30: Global IPF market 2015-2020 ($ billions)
Exhibit 31: Key drivers and challenges for global IPF drugs market
Exhibit 32: Global respiratory drugs market: YoY revenue and growth based on respiratory diseases 2015-2020
Exhibit 33: Global respiratory drugs market by geography 2015
Exhibit 34: Global respiratory drugs market revenue by geography 2015-2020 ($ billions)
Exhibit 35: Respiratory drugs market in Americas 2015-2020 ($ billions)
Exhibit 36: Respiratory drugs market in EMEA 2015-2020 ($ billions)
Exhibit 37: Respiratory drugs market in APAC 2015-2020 ($ billions)
Exhibit 38: Global respiratory drugs market; YoY revenue and growth based on geography 2015-2020
Exhibit 39: Impact of drivers
Exhibit 40: Impact of drivers and challenges
Exhibit 41: Drugs that converted from Rx to OTC
Exhibit 42: Global respiratory drugs market share analysis 2015
Exhibit 43: Top selling respiratory drugs based on their revenue in 2014
Exhibit 44: AstraZeneca: Percentage share of products sales by therapy area 2014
Exhibit 45: AstraZeneca: YoY growth and revenue of Symbicort 2012-2014 ($ billions)
Exhibit 46: AstraZeneca: YoY growth and revenue of Pulmicort 2012-2014 ($ billions)
Exhibit 47: AstraZeneca: Key takeaways
Exhibit 48: Boehringer Ingelheim: YoY growth and revenue of Spiriva 2012-2014 ($ billions)
Exhibit 49: Boehringer Ingelheim: YoY growth and revenue of Combivent 2012-2014 ($ millions)
Exhibit 50: Boehringer Ingelheim: Key takeaways
Exhibit 51: F. Hoffmann-La Roche: YoY growth and revenue of Xolair in the US 2012-2014 ($ millions)
Exhibit 52: F. Hoffmann-La Roche: YoY growth and revenue of Pulmozyme 2012-2014 ($ millions)
Exhibit 53: F. Hoffmann-La Roche: Key takeaways
Exhibit 54: GlaxoSmithKline: Percentage share of products sales by therapy area 2014
Exhibit 55: GlaxoSmithKline: YoY growth and revenue of Seretide/Advair 2012-2014 ($ billions)
Exhibit 56: GlaxoSmithKline: YoY growth and revenue of Flixotide/Flovent 2012-2014 ($ billions)
Exhibit 57: GlaxoSmithKline: YoY growth and revenue of Ventolin 2012-2014 ($ billions)
Exhibit 58: GlaxoSmithKline: YoY growth and revenue of Avamys/Veramyst 2012-2014 ($ millions)
Exhibit 59: GlaxoSmithKline: YoY revenue of Avamys/Veramyst 2013 and 2014 ($ millions)
Exhibit 60: GlaxoSmithKline: Key takeaways
Exhibit 61: Merck: YoY growth and revenue of Nasonex 2012-2014 ($ billions)1
Exhibit 62: Merck: YoY growth and revenue of Singulair 2012-2014 ($ billions)2
Exhibit 63: Merck: YoY growth and revenue of Clarinex 2012-2014 ($ millions)2
Exhibit 64: Merck: Key takeaways4
Exhibit 65: Novartis: YoY growth and revenue of Xolair (outside the US) 2012-2014 ($ millions)6
Exhibit 66: Novartis: YoY growth and revenue of TOBI 2012-2014 ($ millions)6
Exhibit 67: Novartis: YoY growth and revenue of Onbrez Breezhaler 2012-2014 ($ millions)7
Exhibit 68: Novartis: YoY growth and revenue of Seebri Breezhaler 2012-2014 ($ millions)7
Exhibit 69: Novartis: YoY revenue of Ultibro Breezhaler 2013 and 2014 ($ millions)8
Exhibit 70: Novartis: YoY growth and revenue of Foradil Aerolizer sold outside the US 2012-2014 ($ millions)8
Exhibit 71: Novartis: Key takeaways9
Note: Product cover images may vary from those shown
3 of 5

Loading
LOADING...

4 of 5

FEATURED COMPANIES

  • Abbott
  • Aurobindo
  • Cipla
  • GNI Group Ltd
  • Perrigo
  • Skyepharma
  • MORE
New Report Released: – Global Respiratory Drugs Market 2016-2020

The author of the report recognizes the following companies as the key players in the global respiratory drugs market: AstraZeneca, Boehringer Ingelheim, F.Hoffman-La Roche, GlaxoSmithKline, Merck, and Novartis.

Other Prominent Vendors in the market are: Abbott, Actavis, Afferent Pharmaceuticals, Alere, Almirall, Amgen, AptarGroup, Astellas, Aurobindo, Axis Shield, Baxter, Bayer, Biogen, Biotest, Bristol-Myers Squibb, Chiesi Farmaceutici, Cipla, Cytos, Dainippon Sumitomo, Dr. Reddy's Laboratories, FibroGen, Gilead Sciences, Glenmark, GNI Group Ltd, Horizon Pharma, ImmuneWorks, MediciNova, MedImmune, Mylan, Ono Pharmaceutical, Orchid Chemicals and Pharmaceuticals, Perrigo, Pfizer, Promedior, Prometheus, ProMetic Life Sciences, Ranbaxy, Rottapharm Madaus, Sanofi, Shionogi, Siemens Healthcare Diagnostics, Skyepharma, Sosei, Sunovion, Takeda Pharmaceutical , Teva, Theravance, United Therapeutics, Vectura, Vertex, and Zai Lab.

Commenting on the report, an analyst from the research team said: “A noteworthy trend in the respiratory drugs market is the use of biologics. In recent times, biologics are increasingly becoming the preferred choice to treat respiratory diseases, and they act by blocking the interleukins and reducing inflammation caused in the respiratory tract. For example, Xolair (omalizumab) by Genentech and Novartis is the only approved biologic drug for the treatment of asthma.”

According to the report, a key growth driver is the rising prevalence of respiratory diseases around the world. The CDC reported that as of May 2011, about 25 million Americans, which isone in 12 individuals in the US, had asthma. In 2015, the National Institute of Allergy and Infectious Diseases (NIAID) reported that globally about 250 million people had asthma. According to the WHO factsheet 2016, approximately 8% of the Swiss population, four million Germans, three million Japanese, and 15-20 million Indians are estimated to have asthma. Many respiratory occur due to genetic factors and lifestyle factors such as vehicular pollution and exposure to animals or pets. Rising prevalence of respiratory diseases results in more people seeking treatment, increasing the intake of medicines, thereby contributing to the respiratory drugs market.

Further, the report states that a major challenge with the potential to hamper market growth is the unknown etiology of respiratory problems like asthma and idiopathic pulmonary fibrosis.

The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market and vendor landscape in addition to a SWOT analysis of the key vendors.
Note: Product cover images may vary from those shown
5 of 5
- AstraZeneca
- Boehringer Ingelheim
- F.Hoffman-La Roche
- GlaxoSmithKline
- Merck
- Novartis
- Abbott
- Actavis
- Afferent Pharmaceuticals
- Alere
- Almirall
- Amgen
- AptarGroup
- Astellas
- Aurobindo
- Axis Shield
- Baxter
- Bayer
- Biogen
- Biotest
- Bristol-Myers Squibb
- Chiesi Farmaceutici
- Cipla
- Cytos
- Dainippon Sumitomo
- Dr. Reddy's Laboratories
- FibroGen
- Gilead Sciences
- Glenmark
- GNI Group Ltd
- Horizon Pharma
- ImmuneWorks
- MediciNova
- MedImmune
- Mylan
- Ono Pharmaceutical
- Orchid Chemicals and Pharmaceuticals
- Perrigo
- Pfizer
- Promedior
- Prometheus
- ProMetic Life Sciences
- Ranbaxy
- Rottapharm Madaus
- Sanofi
- Shionogi
- Siemens Healthcare Diagnostics
- Skyepharma
- Sosei
- Sunovion
- Takeda Pharmaceutical
- Teva
- Theravance
- United Therapeutics
- Vectura
- Vertex
- Zai Lab.
Note: Product cover images may vary from those shown
6 of 5
Note: Product cover images may vary from those shown
Adroll
adroll